We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
A revised description of cannabinoid-based drugs is needed to ban a dangerous new generation of legal highs, says the Advisory Council on the Misuse of Drugs (ACMD).
First published during the 2016 to 2019 May Conservative government
Joint VMD and Veterinary Products Committee (VPC) open information day on Wednesday 18 November.
The Home Secretary has formally commissioned the Advisory Council on the Misuse of Drugs (ACMD) to conduct a longer-term review of cannabis-based products for medicinal use.
The government responds to the ACMD reports on cannabis-based products for medicinal use (CBPMs) in humans.
Barriers to Research working group calls for written evidence about barriers to legitimate research for controlled drugs, excluding synthetic cannabinoids.
Employment Tribunal decision.
A framework for the assessment of the impact of rescheduling cannabis-based products for medicinal use (CBPMs).
Details of the joint VMD and VPC open information event.
The ACMD has recommended that cannabis-derived medicinal products should be placed in Schedule 2 of the Misuse of Drugs Regulations 2001.
First published during the 2022 to 2024 Sunak Conservative government
Use of the Chembio Inc. Dual Path Platform VetB (DPP) test on badgers (Meles meles).
The Advisory Council on the Misuse of Drugs response to the consultation by NICE on the draft scope of their guidance on cannabis-based products for medicinal use.
New pharmacokinetic data show mean exposure of darunavir (brand name Prezista) boosted with cobicistat (available in combination in Rezolsta▼, Symtuza▼) to be lower during the second and third trimesters of pregnancy than during 6–12 weeks postpartum. Low darunavir exposure may...
Letter from Kit Malthouse MP to Professor Owen Bowden-Jones, Chair of the Advisory Council on the Misuse of Drugs (ACMD).
First published during the 2019 to 2022 Johnson Conservative government
The Government responds to the ACMD’s further advice on synthetic cannabinoids and advice on methoxetamine and related compounds.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).